Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr435.70 DKK
Change Today -1.90 / -0.43%
Volume 288.2K
As of 11:07 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

coloplast-b (COLOB) Snapshot

Open
kr435.00
Previous Close
kr437.60
Day High
kr437.70
Day Low
kr433.10
52 Week High
04/15/15 - kr581.00
52 Week Low
06/16/15 - kr413.10
Market Cap
95.9B
Average Volume 10 Days
497.9K
EPS TTM
kr15.36
Shares Outstanding
202.0M
EX-Date
05/7/15
P/E TM
28.4x
Dividend
kr12.00
Dividend Yield
2.75%
Current Stock Chart for COLOPLAST-B (COLOB)

Related News

No related news articles were found.

coloplast-b (COLOB) Related Businessweek News

No Related Businessweek News Found

coloplast-b (COLOB) Details

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company offers ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. Its ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. The company also provides urology care products for people suffering from diseases and symptoms of the urinary system, such as urinary incontinence, kidney stones, enlarged prostate, impotence, and pelvic floor prolapse, as well as the male reproductive system. Its disposable surgical devices include prostate catheters and stents used for urological and gynaecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, the company provides continence care products comprising SpeediCath catheters that offer catherisation for both genders; and Peristeen, an anal irrigation system for controlled emptying of the bowels. Further, it offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products consisting of disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, Coloplast A/S offers Interdry AG, a textile placed in a skin fold to absorb moisture for the treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies. Coloplast A/S was founded in 1954 and is headquartered in Humlebaek, Denmark.

9,000 Employees
Last Reported Date: 05/5/15
Founded in 1954

coloplast-b (COLOB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr8.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr1.0M
Executive Vice President of Global Operations
Total Annual Compensation: kr1.3M
Executive Vice President of Chronic Care
Total Annual Compensation: kr1.6M
Compensation as of Fiscal Year 2014.

coloplast-b (COLOB) Key Developments

Coloplast A/S Provides Earnings Guidance for the Full Year of 2015

Coloplast A/S provided earnings guidance for the full year of 2015. The company's revenue expectations for the full-year are revised from an organic revenue growth of 8-9% to an organic revenue growth of around 7%. The expected EBIT margin for 2014/15 is lowered from around 34% at constant exchange rates and in DKK to around 32%, both at constant exchange rates and in DKK. The EBIT margin is lowered partly due to expected lower sales. Guidance for capital expenditure remains unchanged at around DKK 650 million, and the effective tax rate is still expected to be about 24%.

Coloplast A/S, 2015 Guidance/Update Call, Jun 16, 2015

Coloplast A/S, 2015 Guidance/Update Call, Jun 16, 2015

Coloplast A/S Announces Interim Dividend, Payable on 11 May 2015; Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Coloplast A/S to pay an interim dividend of DKK 4.50 per share, for a dividend pay-out of DKK 953 million. The last day company's shares will trade cum dividend will be 6 May 2015, and they will trade ex-dividend starting on 7 May 2015. Dividends will be paid to shareholders on 11 May 2015. The company announced unaudited consolidated earnings results for the second quarter and six months ended March 31, 2014. For the six months, the company's revenue was DKK 6,748 million compared with DKK 6,080 million a year ago. Operating profit before interest, tax, depreciation and amortization was DKK 2,452 million compared with DKK 1,206 million a year ago. Operating profit was DKK 2,213 million compared with DKK 997 million a year ago. Profit before tax was DKK 2,120 million compared with DKK 1,022 million a year ago. Net profit for the period was DKK 1,612 million or DKK 7.56 per diluted share compared with DKK 761 million or DKK 3.54 per diluted share a year ago. Cash flow from operating activities was DKK 863 million compared with DKK 997 million a year ago. The change was mainly due to higher tax payments resulting from a voluntary on-account payment of DKK 450 million. Investments in property, plant and equipment, gross was DKK 315 million compared with DKK 210 million a year ago. Investments in intangible assets were DKK 10 million compared with DKK 10 million a year ago. Investments in land and buildings were DKK 6 million. Investments in plant and machinery were DKK 8 million compared with DKK 18 million a year ago. Investments in property, plant and equipment under construction was DKK 301 million compared with DKK 192 million a year ago. Return on equity was 51% compared with 24% a year ago. Earnings per share before special items, diluted were DKK 7.56 compared with DKK 7.07 a year ago. CapEx increased to DKK 325 million, up 48% compared to last year. For the quarter, the company's revenue was DKK 3,447 million compared with DKK 3,017 million a year ago. Operating profit before interest, tax, depreciation and amortization was DKK 1,258 million compared with DKK 87 million a year ago. Operating profit was DKK 1,137 million compared with operating loss of DKK 16 million a year ago. Profit before tax was DKK 1,072 million compared with loss of DKK 18 million a year ago. Net profit for the period was DKK 815 million or DKK 3.82 per diluted share compared with net loss of DKK 19 million or DKK 0.09 per diluted share a year ago. Cash flow from operating activities was DKK 217 million compared with DKK 395 million a year ago. Investments in property, plant and equipment, gross was DKK 168 million compared with DKK 100 million a year ago. Return on equity was 55% compared with negative return on equity of 1% a year ago. As on March 31, 2015, the company's net asset value per share was DKK 29. Earnings per share before special items, diluted were DKK 3.82 compared with DKK 3.44 a year ago. For fiscal 2015, the company continues to expect organic revenue growth of 8%-9% but now 13%-14% in DKK. Capital expenditure is still expected to be around DKK 650 million. The effective tax rate is still expected to be about 24%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COLOB:DC kr435.70 DKK -1.90

COLOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $171.36 USD +0.06
Hill-Rom Holdings Inc $54.25 USD +0.04
Teleflex Inc $137.58 USD +1.72
William Demant Holding A/S kr501.50 DKK -7.00
View Industry Companies
 

Industry Analysis

COLOB

Industry Average

Valuation COLOB Industry Range
Price/Earnings 29.6x
Price/Sales 7.3x
Price/Book 14.7x
Price/Cash Flow 28.1x
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLOPLAST-B, please visit www.coloplast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.